Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

76 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease.
Nielsen SE, Schjoedt KJ, Rossing K, Persson F, Schalkwijk CG, Stehouwer CD, Parving HH, Rossing P. Nielsen SE, et al. Among authors: rossing k, rossing p. J Renin Angiotensin Aldosterone Syst. 2013 Jun;14(2):161-6. doi: 10.1177/1470320312460290. Epub 2012 Oct 29. J Renin Angiotensin Aldosterone Syst. 2013. PMID: 23108194 Clinical Trial.
Urinary proteomics in diabetes and CKD.
Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, Good DM, Coon JJ, Tarnow L, Rossing P; PREDICTIONS Network. Rossing K, et al. Among authors: rossing p. J Am Soc Nephrol. 2008 Jul;19(7):1283-90. doi: 10.1681/ASN.2007091025. Epub 2008 Apr 30. J Am Soc Nephrol. 2008. PMID: 18448586 Free PMC article.
Beneficial impact of spironolactone in diabetic nephropathy.
Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, Parving HH. Schjoedt KJ, et al. Among authors: rossing k, rossing p. Kidney Int. 2005 Dec;68(6):2829-36. doi: 10.1111/j.1523-1755.2005.00756.x. Kidney Int. 2005. PMID: 16316360 Clinical Trial.
76 results